Phosphodiesterase (PDE) Inhibitors Market Analysis

The market is segmented by drug class, type and application, out of which, the erectile dysfunction sub-segment of application segment is anticipated to hold leading shares in the phosphodiesterase (PDE) inhibitors market on account of various factors, such as growing incidences of diseases such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, hyperlipidemia, and rising consumption of certain medicines and substance abuse can lead to erectile dysfunction. According to the World Health Organization (WHO), the global prevalence of erectile dysfunction is projected to increase from 150 million in 1995 to 320 million men in 2025. Additionally, the oral segment of the type sector is anticipated to witness a modest growth owing to factors such as low cost, and accurate dosage and stability.

Our in-depth analysis of the global market includes the following segments:

By Drug Class

Selective PDE Inhibitors
PDE-1
PDE-2
PDE-3
PDE-4
PDE-5
Others
Non-Selective PDE Inhibitors

By Type

Oral
Typical
Other

Application

Respiratory Disease
Erectile Dysfunction
Vascular Disease
Diabetes
Others

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of phosphodiesterase inhibitors is assessed at USD 3.3 billion.

Phosphodiesterase (PDE) Inhibitors Market size was valued at USD 3.15 billion in 2023 and is expected to reach USD 6.8 billion by 2036, registering around 6.1% CAGR during the forecast period i.e., between 2024-2036.

North America industry is likely to hold largest revenue share by 2036, on account of factors such as presence of large pharmaceutical companies and increasing lifestyle changes.

The major players in the market are Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., Vivus Inc, AstraZeneca plc, Celgene Corporation, and others.

Phosphodiesterase (PDE) Inhibitors Market Analysis